Skip to content

Study · Case report or series · n = 1 · 2024

1 result

GLP-1 Agonists Can Affect Mood: A Case of Worsened Depression on Ozempic (Semaglutide).

Manoharan SVRR, Madan R

Innovations in clinical neuroscience1 Apr 2024Cited by 7 (Europe PMC)

PMID38938530 (opens in a new tab)PepBankPUB-38938530
Publisher pageAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    In one patient, semaglutide treatment was possibly linked to worsened depression.

    In plain wordsIn one patient, semaglutide was possibly linked to worse depression. This is a single case and does not show cause.

    Peptide
    Semaglutide
    Outcome
    IncreaseWorsened depression
    Study

    n = 1

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Title
    GLP-1 Agonists Can Affect Mood: A Case of Worsened Depression on Ozempic (Semaglutide).
    1 context sentence
    Summary · context
    This case report underscores the adverse mood changes possibly linked to semaglutide and the need for further study in this area.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.